Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I\II Clinical Trial of RV-001 for for Gene-Agnostic Retinitis Pigmentosa.

Next Previous
Trial Profile

Phase I\II Clinical Trial of RV-001 for for Gene-Agnostic Retinitis Pigmentosa.

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RV-001-Restore-Vision (Primary)
  • Indications Retinitis pigmentosa
  • Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

  • 25 Feb 2025 New trial record
  • 13 Feb 2025 According to Restore Vision media release, the first patient dosed in this study at Keio University Hospital.
  • 04 Feb 2025 According to Restore Vision media release, the company has closed 600M yen funding ( (total 300M yen through Japan Agency for Medical Research and Development (AMED) received jointly with Keio University), proceeds will be used to start clinical trials of RV-001 as early as possible.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top